249 related articles for article (PubMed ID: 3929265)
1. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
[No Abstract] [Full Text] [Related]
2. [Treatment of advanced cancer of the prostate with an analog of LHRH, buserelin].
Wenderoth UK; Jacobi GH
Ann Urol (Paris); 1986; 20(2):95-7. PubMed ID: 3087269
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
[TBL] [Abstract][Full Text] [Related]
4. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
[No Abstract] [Full Text] [Related]
5. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with single and multiple subcutaneous administration of LHRH analog Buserelin (Hoe 766) in prostatic carcinoma: endocrinological study of optimum subcutaneous doses].
Niijima T; Isurugi K; Kawabe K; Kinoshita K; Asano M; Nakauchi K; Fujita K; Nishimura Y; Nitoh H; Yokoyama M
Hinyokika Kiyo; 1988 Jul; 34(7):1297-307. PubMed ID: 2459944
[TBL] [Abstract][Full Text] [Related]
7. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
[TBL] [Abstract][Full Text] [Related]
8. Metastatic prostate cancer under long term pernasal buserelin or intramuscular decapeptyl depot treatment.
Wenderoth UK; Spindler HW; Ehrenthal W; von Wallenberg H; Happ J; Jacobi GH
Prog Clin Biol Res; 1987; 243A():207-20. PubMed ID: 2958851
[No Abstract] [Full Text] [Related]
9. Kinetic evaluation of the effect of LHRH analog on prostatic cancer using transrectal ultrasonotomography.
Kojima M; Watanabe H; Ohe H; Miyashita H; Inaba T
Prostate; 1987; 10(1):11-7. PubMed ID: 3103113
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
11. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
12. The effects of buserelin on the hormonal states in PCOD.
Willemsen WN; Franssen AM; Rolland R; Vemer HM
Prog Clin Biol Res; 1986; 225():377-89. PubMed ID: 3097673
[No Abstract] [Full Text] [Related]
13. [Treatment of prostatic cancer with an LH-RH analog].
Fuse H; Zama S; Akimoto S; Shimazaki J; Murakami S; Igarashi T
Hinyokika Kiyo; 1986 Aug; 32(8):1113-9. PubMed ID: 3098063
[TBL] [Abstract][Full Text] [Related]
14. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
15. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
16. Influence of LH-RH agonists on the growth and hormonal environment of breast and prostate cancer.
Nicholson RI; Walker KJ
Chemioterapia; 1985 Jun; 4(3):249-51. PubMed ID: 3161643
[TBL] [Abstract][Full Text] [Related]
17. [Phase I study with LH-RH agonist, ICI 118630].
Usami M; Kotake T; Sonoda T
Hinyokika Kiyo; 1986 Mar; 32(3):493-501. PubMed ID: 2942018
[TBL] [Abstract][Full Text] [Related]
18. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
19. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
20. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
